Glenmark scrip plunges on suspension of pain drug trials

Glenmark Pharmaceuticals on Friday said the clinical trials for its experimental pain treatment molecule has been suspended, following which its scrips plunged 20 per cent on the bourse.

The details can be read here.
Other links: The economic times